David Sleat is a Professor in the Dept. of Biochemistry and Molecular Biology of the Robert Wood Johnson Medical School and Executive Director of the CABM Biological Mass Spectrometry Facility. His graduate training at the John Innes Institute and postdoctoral studies at Cornell University and the Cleveland Clinic Foundation were in the field of virology. Sleat joined the laboratory of Dr. Peter Lobel at the CABM in 1993 and was appointed to the faculty of UMDNJ in 1996. Sleat and Lobel identified the genetic basis for a neurodegenerative disease of children, late-infantile neuronal ceroid lipofuscinosis (LINCL) in 1998 and their subsequent research provided a platform for the development of an enzyme-replacement therapy that was approved by the FDA and EMA in 2017. They continue to search for improved treatments for LINCL and related diseases.